Many people exploring options for firmer, more resilient skin come across copper tripeptide-1 in serums and topical formulations. Often referred to by its shorthand GHK-Cu, this compound is positioned as a skin renewal ingredient rather than a prescription drug.
Key takeaways
- Marketed as a topical ingredient intended to firm skin and reduce visible signs of premature aging.
- Carries the pharmacologic classification "methylating agent" on its label.
- One registered clinical trial is currently tracking its use in wound healing.
- That trial is a Phase 2 study and is still recruiting participants.
- No adverse event reports were available in the reviewed safety dataset.
What copper tripeptide-1 is
Copper tripeptide-1 (PubChem CID 71587328) is labeled as a methylating agent, a broad pharmacologic classification used on its product labeling. The specific way it acts on skin tissue is not detailed in the available label data.
What copper tripeptide-1 is approved for
The labeled product, sold as YVTYVT Copper Peptides Facial Serum, is positioned to help repair skin, improve tightness, and counter visible signs of premature aging. It is also described as supporting the skin's natural density and firmness with continued use. This is a cosmetic labeling claim rather than a treatment for a diagnosed medical condition, and no boxed warning is associated with the product.
What the evidence shows
One clinical trial referencing this compound is currently registered. That study, a Phase 2 trial, is evaluating a topical GHK-Cu gel for acute skin wound healing and is actively recruiting participants.